A Retrospective Analysis of ADC Target Antigen Expression Profiles and Their Prognostic Significance in Endometrial Cancer

A Retrospective Analysis of ADC Target Antigen Expression Profiles and Their Prognostic Significance in Endometrial Cancer - A Retrospective Analysis of ADC Target Antigen Expression Profiles and Their Prognostic Significance in Endometrial Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061689

Enrollment

100

Registered

2026-05-26

Start date

2026-05-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Patients who are currently attending or have previously attended National Cancer Center Hospital East, National Cancer Center, Japan. 2. Patients for whom new comprehensive consent for the use of biobank specimens has been obtained. 3. Patients who were 18 years of age or older at the time of obtaining comprehensive consent. 4. Patients who were histologically diagnosed with stage III or IV endometrial cancer at our hospital between April 1, 2018 and December 31, 2025, and who received initial treatment, or patients with recurrent endometrial cancer. 5. Patients for whom formalin-fixed paraffin-embedded block specimens from surgical or biopsy samples are stored at our hospital.

Exclusion criteria

Exclusion criteria: 1. Cases with insufficient specimens available for the study. 2. Cases in which only cytological examination was performed and histological diagnosis was not confirmed. 3. Cases in which study information was disclosed through an opt-out process and the patient refused to participate in the study. 4. Other cases deemed inappropriate by the principal investigator.

Design outcomes

Primary

Measure	Time frame
To evaluate the association between the expression of each biomarker and overall survival in patients with endometrial cancer who received initial treatment.	—

Secondary

Measure	Time frame
To evaluate the association between individual biomarker expression and progression-free survival. To analyze the correlations between ADC target antigen expression and hormone receptor and PD-L1 expression. To explore biomarker co-expression patterns to assess the potential for combination treatment strategies involving ADCs, hormone therapy, and immunotherapy.	—

Countries

Japan

Contacts

Public ContactSaki Tsuchimochi

National Cancer Center Hospital East Department of Medical Oncology

stsuchim@east.ncc.go.jp04-7133-1111

Outcome results